Immune
Thymosin Alpha-1
Also called Thymalfasin, Zadaxin, Tα1
per administration
A human trial worked out how much to take and how often, so a dosing schedule is shown.
Licensed as a medicine in roughly 35 countries, though never the US.
Quick start
Thymosin Alpha-1 at a glance — the figures, plus how it's commonly run. Reference only, not medical advice.
- Typical dose
- 1.6–1.6 mg per administration
- How often
- 2x per week
- Where
- Subcutaneous — abdomen, thigh, or upper arm Sites and rotation
- Time to steady level
- ~10 hours — about five half-lives
- Storage
- Dry vial kept cold and dark; a mixed vial in the fridge at 2–8 °C. Details
A research and community reference, not medical advice. Figures are descriptive, vary between sources, and are not a recommendation for use.
Key properties
Molecular reference data.
- Formula
- C129H215N33O55
- Mol. weight
- 3,108.3 Da
- CAS
- 62304-98-7
- PubChem CID
- 16130571
External references
Work out your draw
These numbers are a starting point — change any of them.
Vial label
Copy this into your label printer.
Published research contexts for Thymosin Alpha-1 describe 1.6–1.6 mg per administration. Descriptive only, not a recommendation.
Roughly 2 hours in plasma.
An immune-modulating peptide licensed as a medicine in roughly 35 countries but never in the US. Human dosing was subcutaneous, so a schedule table is shown; the amount matches the chronic hepatitis B study and the Zadaxin label.
Dosing schedule
How Thymosin Alpha-1 is commonly stepped up, for reference only.
These are commonly-discussed research protocols shared for educational reference. This is not medical advice and is not a substitute for guidance from a qualified professional.
| Phase | Amount | Frequency | Route |
|---|---|---|---|
| Reported scheduleThe amount and spacing given to trial participants in the chronic hepatitis B study and carried on the Zadaxin label. | 1.6 mg | Twice weekly | SubQ |
Modelled level — 2x per week
1× is the peak after a single dose.
- Steady-state peak
- 1.00× single dose
- Time to steady state
- 10hours
- Administrations
- 2/ week
Read off the modelled curve, not an even-interval formula
About five half-lives
Where these numbers come from
- Andreone P et al., Hepatology 1996A placebo-controlled study of chronic hepatitis B gave thymosin alpha-1 1.6 mg subcutaneously twice weekly to trial participants over about six months.
- Zadaxin (thymalfasin) product labelLicensed as a medicine in roughly 35 countries; the label lists 1.6 mg subcutaneously twice weekly.